Skip to main content
SpringerLink
Log in

Neurofibromatosis Type 2 (NF2)

  • Chapter
  • First Online:
Neurofibromatoses in Clinical Practice

Abstract

Neurofibromatosis type 2 (NF2), Bilateral acoustic neurofibromatosis, Central neurofibromatosis. OMIM #101000. The correct name for the condition is Neurofibromatosis type 2 (NF2). The remaining names are historically due to the overlap with NF1 and previous confusion over the two conditions. The first clear description of NF2 was in 1822 by Wishart.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wishart JH. Case of tumours in the skull, dura mater, and brain. Edinburgh Med Surg J. 1822;18:393-397.

    Google Scholar 

  2. Cushing H. Tumours of the Nervus Acusticus and the Syndrome of the Cerebello-pontine Angle. Philadelphia: WB Saunders; 1917.

    Google Scholar 

  3. Crowe FW, Schull WJ, Neal JV, eds. A Clinical Pathological and Genetic Study of Multiple Neurofibromatosis. Springfield, IL: Charles C. Thomas; 1956.

    Google Scholar 

  4. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature. 1993;363:515-521.

    Article  PubMed  CAS  Google Scholar 

  5. Troffater JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumour suppressor. Cell. 1993;72:791-800.

    Article  Google Scholar 

  6. National Institutes of Health Consensus Development Conference. Statement on neurofibromatosis. Arch Neurol. 1987;45:575-579.

    Article  Google Scholar 

  7. Evans DGR, Huson S, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med. 1992;84:603-618.

    PubMed  CAS  Google Scholar 

  8. Evans DGR, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the north west of England and the UK: I. Prevalence, mutation rate, fitness and confirmation of maternal transmission effect on severity. J Med Genet. 1992;29:841-846.

    Article  PubMed  CAS  Google Scholar 

  9. Evans DGR, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10 year period: higher incidence than previously thought. Otol Neurotol. 2005;26(1):93-97.

    Article  PubMed  Google Scholar 

  10. Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumour prone syndromes: estimates from a UK genetic family register service. Am J Med Genet. 2010;152A(2):327-332.

    Article  PubMed  CAS  Google Scholar 

  11. Antinheimo J, Sankila R, Carpén O, Pukkala E, Sainio M, Jääskeläinen J. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology. 2000;54(1):71-76.

    Article  PubMed  CAS  Google Scholar 

  12. Evans DGR, Wallace A, Trueman L, Strachan T. Mosaicism in classical neurofibromatosis type 2: a common mechanism for ­sporadic disease in tumour prone syndromes? Am J Hum Genet. 1998;63:727-736.

    PubMed  CAS  Google Scholar 

  13. Evans DGR, Ramsden RT, Shenton A, et al. Mosaicism in NF2 an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including MLPA. J Med Genet. 2007;44(7):424-428.

    Article  PubMed  CAS  Google Scholar 

  14. Kluwe L, Mautner VF, Heinrich B, et al. Molecular study of ­frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet. 2003;40:109-114.

    Article  PubMed  CAS  Google Scholar 

  15. Moyhuddin A, Baser ME, Watson C, et al. Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet. 2003;40:459-463.

    Article  PubMed  CAS  Google Scholar 

  16. Kanter WR, Eldridge R, Fabricant R, Allen JC, Koerber T. Central neurofibromatosis with bilateral acoustic neuroma. Genetic, clinical and biochemical distinctions from peripheral neurofibromatosis. Neurology. 1980;30:851-859.

    Article  PubMed  CAS  Google Scholar 

  17. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet. 1994;52:450-451.

    Article  PubMed  CAS  Google Scholar 

  18. Mautner VF, Lindenau M, Baser ME, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery. 1996;38:880-885.

    Article  PubMed  CAS  Google Scholar 

  19. Evans DGR, Ramsden R, Birch J. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child. 1999;81:496-499.

    Article  PubMed  CAS  Google Scholar 

  20. Trivedi R, Byrne J, Huson SM, Donaghy M. Focal amyotrophy in neurofibromatosis 2. J Neurol Neurosurg Psychiatry. 2000;69(2):257-261.

    Article  PubMed  CAS  Google Scholar 

  21. Sperfeld AD, Hein C, Schroder JM, Ludolph AC, Hanemann CO. Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain. 2002;125:996-1004.

    Article  PubMed  CAS  Google Scholar 

  22. Evans DGR, Newton V, Neary W, et al. Use of MRI and audiological tests in pre-symptomatic diagnosis of type 2 neurofibromatosis (NF2). J Med Genet. 2000;37:944-947.

    Article  PubMed  CAS  Google Scholar 

  23. King A, Biggs N, Ramsden RT, Wallace A, Gillespie J, Evans DGR. Spinal tumours in neurofibromatosis type 2: Is emerging knowledge of genotype predictive of natural history? J Neurosurg Spine. 2005;2(5):574-579.

    Article  PubMed  Google Scholar 

  24. Evans DGR, Baser ME, O’Reilly B, et al. Management of the patient and family with Neurofibromatosis 2: a consensus conference statement. Brit J Neurosurg. 2005;19:5-12.

    Article  CAS  Google Scholar 

  25. Evans DGR, Ramsden RT, Shenton A, et al. Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma? Clin Genet. 2007;71(4):354-358.

    Article  PubMed  CAS  Google Scholar 

  26. Evans DGR, Ramsden RT, Shenton A, et al. What are the implications in individuals with unilateral vestibular schwannoma and other neurogenic tumours? J Neurosurg. 2008;108(1):92-96.

    Article  PubMed  Google Scholar 

  27. Seizinger BR, Rouleau GA, Ozelius LG, et al. Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene. Cell. 1987;49:589-594.

    Article  PubMed  CAS  Google Scholar 

  28. Rouleau G, Seizinger BR, Ozelius LG, et al. Genetic linkage analysis of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature. 1987;329:246-248.

    Article  PubMed  CAS  Google Scholar 

  29. Parry DM, MacCollin M, Kaiser-Kupfer MI, et al. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet. 1996;59:529-539.

    PubMed  CAS  Google Scholar 

  30. Ruttledge MH, Andermann AA, Phelan CM, et al. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet. 1996;59:331-342.

    PubMed  CAS  Google Scholar 

  31. Kluwe L, Bayer S, Baser ME, Hazim W, Haase W, Funsterer C. Mautner VF Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes [published erratum in Hum Genet 1997;99(2):292]. Hum Genet. 1996;98:534-538.

    Article  PubMed  CAS  Google Scholar 

  32. Kluwe L, MacCollin M, Tatagiba M, et al. Phenotypic variability associated with 14 splice-site mutations in the NF2 gene. Am J Med Genet. 1998;77:228-233.

    Article  PubMed  CAS  Google Scholar 

  33. Evans DGR, Trueman L, Wallace A, Mason S, Strachan T. Genotype/phenotype correlations in type 2 neurofibromatosis: evidence for more severe disease with truncating mutations. J Med Genet. 1998;35:450-455.

    Article  PubMed  CAS  Google Scholar 

  34. Baser ME, Kuramoto L, Joe H, et al. Genotype-phenotype correlations for nervous system tumours in neurofibromatosis 2: a population-based study. Am J Hum Genet. 2004;75:231-239.

    Article  PubMed  CAS  Google Scholar 

  35. Baser ME, Kuramoto L, Woods RH, et al. The location of constitutional neurofibromatosis 2 (NF2) splice-site mutations is associated with the severity of NF2. J Med Genet. 2005;42(7):540-546.

    Article  PubMed  CAS  Google Scholar 

  36. Selvanathan SK, Shenton A, Ferner R, et al. Further genotype-phenotype correlations in neurofibromatosis type 2. Clin Genet. 2010;77(2):163-170.

    Article  PubMed  CAS  Google Scholar 

  37. Tsilchorozidou T, Menko F, Lalloo F, et al. Constitutional rearrangements of chromosome 22 as a cause of neurofibromatosis type 2. J Med Genet. 2004;41(7):529-534.

    Article  PubMed  CAS  Google Scholar 

  38. Kluwe L, Nygren AO, Errami A, et al. Screening for large mutations of the NF2 gene. Genes Chromosomes Cancer. 2005;42(4):384-391.

    Article  PubMed  CAS  Google Scholar 

  39. MacCollin M, Chiocca EA, Evans DG, et al. Diagnostic criteria for schwannomatosis. Neurology. 2005;64(11):1838-1845.

    Article  PubMed  CAS  Google Scholar 

  40. Murray A, Hughes TAT, Neal JW, Howard E, Evans DGR, Harper PS. A case of multiple cutaneous schwannomas; schwannomatosis or neurofibromatosis type 2? J Neurol Neurosurg Psychiatry. 2006;77(2):269-271.

    Article  PubMed  CAS  Google Scholar 

  41. Baser ME, Friedman JM, Evans DG. Increasing the specificity of diagnostic criteria for schwannomatosis. Neurology. 2006;66(5):730-732.

    Article  PubMed  Google Scholar 

  42. Hadfield KD, Newman WG, Bowers NL, et al. Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J Med Genet. 2008;45(6):332-339.

    Article  PubMed  CAS  Google Scholar 

  43. Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DGR. Evaluation of diagnostic criteria for neurofibromatosis 2. Neurology. 2002;59(11):1759-1765.

    Article  PubMed  CAS  Google Scholar 

  44. Evans DGR, Ramsden R, Huson SM, et al. Type 2 neurofibromatosis: the need for supraregional care. J Laryngol Otol. 1993;107:401-406.

    Article  PubMed  CAS  Google Scholar 

  45. Slattery WH, Brackmann DE, Hitselberger W. Hearing preservation in neurofibromatosis type 2. Am J Otol. 1998;19:638-643.

    PubMed  Google Scholar 

  46. Baser ME, Friedman JM, Aeschilman D, et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet. 2002;71:715-723.

    Article  PubMed  Google Scholar 

  47. Sobel RA, Wang Y. Vestibular (acoustic) schwannomas: histological features in neurofibromatosis 2 and in unilateral cases. J Neuropathol Exp Neurol. 1993;52:106-113.

    Article  PubMed  CAS  Google Scholar 

  48. Rowe JG, Radatz M, Walton L, Kemeny AA. Stereotactic radiosurgery for type 2 neurofibromatosis acoustic neuromas: patient selection and tumour size. Stereotact Funct Neurosurg. 2002;79:107-116.

    Article  PubMed  Google Scholar 

  49. Rowe JG, Radatz MW, Walton L, Soanes T, Rodgers J, Kemeny AA. Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis. J Neurol Neurosurg Psychiatry. 2003;74(9):1288-1293.

    Article  PubMed  CAS  Google Scholar 

  50. Baser ME, Evans DGR, Jackler RK, Sujansky E, Rubenstein A. Malignant peripheral nerve sheath tumours, radiotherapy, and neurofibromatosis 2. Br J Cancer. 2000;82:998.

    Article  PubMed  CAS  Google Scholar 

  51. Evans DGR, Birch JM, Ramsden RT, Sharif S, Baser ME. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour-prone syndromes. J Med Genet. 2006;43(4):289-294.

    Article  PubMed  CAS  Google Scholar 

  52. Evans DG, Kalamarides M, Hunter-Schaedle K, et al. Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res. 2009;15:5032-5039.

    Article  PubMed  Google Scholar 

  53. Hanemann CO. Magic but treatable? Tumours due to loss of merlin. Brain. 2008;131(pt 3):606-615.

    Article  PubMed  CAS  Google Scholar 

  54. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361(4):358-367.

    Article  PubMed  CAS  Google Scholar 

  55. Mautner VF, Nguyen R, Kutta H, et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol. 2010;12(1):14-18.

    Article  PubMed  Google Scholar 

  56. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet. 1994;52:450-451.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Manchester Academic Health Science Centre, Saint Mary’s Hospital, Manchester, UK

    D. Gareth R. Evans (Consultant Clinical Geneticist)

Authors
  1. D. Gareth R. Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag London Limited

About this chapter

Cite this chapter

Evans, D.G.R. (2011). Neurofibromatosis Type 2 (NF2). In: Neurofibromatoses in Clinical Practice. Springer, London. https://doi.org/10.1007/978-0-85729-629-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-629-0_2

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-628-3

  • Online ISBN: 978-0-85729-629-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation